Processa Pharmaceuticals Files Base Prospectus For Up To $50M In Securities; Covers Up To $2.4M Of Common Stock To Be Issued And Sold Under Sales Agreement With A.G.P./Alliance Global Partners
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals has filed a base prospectus for up to $50 million in securities, including up to $2.4 million of common stock to be issued and sold under a sales agreement with A.G.P./Alliance Global Partners.
May 21, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Processa Pharmaceuticals has filed a base prospectus for up to $50 million in securities, including up to $2.4 million of common stock to be issued and sold under a sales agreement with A.G.P./Alliance Global Partners.
The filing of a base prospectus for a significant amount of securities, including common stock, often leads to concerns about potential dilution among investors. This can result in downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100